Skip to content. | Skip to navigation

Advanced Search…
Personal tools
Sections
 
You are here: Home > Basic Research > Faculty > Haval Shirwan, Ph.D.

Haval Shirwan, Ph.D.

by Eaves JR,Baxter Slaten — last modified Nov 16, 2011 11:07 AM

 

Dr. Shirwan

 

Professor, Department of Microbiology and Immunology

Hamilton Chair in Autoimmune Disease

Research Interests

 

Immunomodulation using proprietary novel recombinant proteins under clinically applicable protocols for therapeutic purposes with major focus on:

  • Type 1 diabetes
  • Graft rejection
  • Bone marrow transplantation
  • Vaccines (cancer and infectious diseases)

 

Professional Bio

 

2009 - present
 Dr. Michael and Joan Hamilton Endowed Chair in Autoimmune Disease, School of Medicine, University of Louisville, Louisville, KY
 2004 - present
 Professor, Department of Microbiology and Immunology, School of Medicine, University of Louisville, Louisville, KY
 2003 - present
 James Brown Cancer Center , the Stem Cell Biology and Tumor Immunology Programs, University of Louisville , Louisville , KY
 2002 - present
 Member, Center for Genetics and Molecular Medicine, University of Louisville , KY
 2002 - 2009
 University Scholar, School of Medicine, University of Louisville, Louisville, KY
 2000 - present
 Director, Molecular Immunomodulation Program, Institute for Cellular Therapeutics, University of Louisville, Louisville, KY
 2000 - 2004
 Associate Professor, Department of Microbiology and Immunology, School of Medicine, University of Louisville, Louisville, KY
 1998 - 2000
 Associate Professor, Department of Surgery, School of Medicine, University of Louisville, Louisville, KY
 1998 - 1998
 Director, Molecular Biology Program, Institute for Cellular Therapeutics, Allegheny University of the Health Sciences, Philadelphia, PA
 1997 - 1998
 Associate Professor, Department of Surgery, Allegheny University of the Health Sciences, Philadelphia, PA
 1997 - 1998 Director, Molecular Biology Program, Institute for Cellular Therapeutics, Allegheny University of the Health Sciences, Philadelphia, PA
 1995 - 1997
 Associate Director, Transplantation Biology Research Laboratory, National Institute of Transplantation, St. Vincent Medical Center, Los Angeles, CA
 1995 - 1995
 Associate Director, Transplantation Biology Research Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA
 1990 - 1995
 Research Scientist II, Transplantation Biology Research Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA
                                 

Patents Issued

  1. Shirwan.  Compositions and methods for caspase-induced apoptosis. Australian Patent 783996. 4/27/06
  2. Shirwan.  Immune modulation with death-receptor-induced apoptosis. Australian Patent 784614. 8/31/06
  3. Shirwan.  Alteration of Cell Membrane with B7. US Patent 7,238,360. 06/03/07
  4. Shirwan, H. Alteration of cell membrane for new functions. Australian Patent 2002216763. 7/2/07
  5. Shirwan, H., K.G. Elpek, and E.S. Yolcu. Immunostimulatory compositions and methods. US Patent 7,598,345. 10/6/2009
  6. Shirwan, H., K.G. Elpek, and E.S. Yolcu. Immunostimulatory compositions and methods. South African Patent 2008/05079
  7. Shirwan, H. Methods and Compositions for Expanding T Regulatory Cells. South African Patent 2008/05080
  8. Shirwan, H., K.G. Elpek, and E.S. Yolcu. In vivo Cell Surface Engineering. South African Patent 2008/05081
  9. Shirwan, H. Methods and Compositions for Expanding T Regulatory Cells. US Patent 7,745,215.  6/29/2010
  10. Shirwan.  Immune modulation with death-receptor-induced apoptosis. EU Patent 1250055. 9/15/10
  11. Shirwan. Fas ligand-avidin/streptavidin fusion proteins US Patent 7,927,602. 8/19/2011
  12. Shirwan, H., K.G. Elpek, and E.S. Yolcu. Immunostimulatory compositions and methods. US patent 8,017,582. 9/13/2011


Selected Peer-Reviewed Recent Publications (out of 88)

  1. Yolcu, E.S. H. Zhao, C. Lacelle, L. Bandura-Morgan, N. Askenasy, and H. Shirwan. Pancreatic islets engineered with SA-FasL protein establish robust localized tolerance by inducing T regulatory cells in mice. J. Immunol. In press.
  2. Kaminitz A., E.S. Yolcu ES, J. Stein, I. Yaniv, H. Shirwan, N. Askenasy. Killer Treg restore immune homeostasis and suppress autoimmune diabetes in prediabetic NOD mice. J. Autoimmunity. 37:39-47, 2011.
  3. Sharma, R.K, R.-H. Schabowsky, A. Srivastava, K. G. Elpek, E.S. Yolcu, and H. Shirwan. Human papillomavirus-16 E7 and 4-1BBL based soluble vaccine eradicates established tumors in a cervical cancer mouse model. Vaccine 28:5794-802, 2010.   
  4. Sharma, R.K., E.S. Yolcu, K.G. Elpek, and H. Shirwan. Tumor cells engineered to codisplay on their surface 4-1BBL and LIGHT costimulatory proteins as a novel vaccine approach for cancer immunotherapy.  Cancer Gene Ther. 17:730-41, 2010.
  5. Sharma, R.K, R.-H. Schabowsky, A. Srivastava, K. G. Elpek, S. Madireddi, H. Zhao, Z. Zhong, R.W. Miller, K.J. MacLeod, E.S. Yolcu, and H. Shirwan. 4-1BB ligand as an effective multifunctional immunomodulator and antigen delivery vehicle for the development of therapeutic cancer vaccines. Cancer Res. 70:3945-54, 2010.
  6. Schabowsky, R-H, R. Sharma, S. Madireddi, A. Srivastava, E. S. Yolcu, and H. Shirwan. ProtEx™ technology for the generation of novel therapeutic cancer vaccines.  Exp. Mol. Path.  86:139-234, 2009.
  7. Sharma, R.K., K.G. Elpek, E. S. Yolcu, R-H Schabowsky, H. Zhao, L. Bandura-Morgan, and H. Shirwan. Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel from of 4-1BBL eradicates established tumors. Cancer Research 69:4319-26, 2009.
  8. Schabowsky, R-H, K. G. Elpek, R. Sharma, E. S. Yolcu, L. Bandura-Morgan, R. Mittler, R. Miller, K. MacLeod, and H. Shirwan. A novel form of 4-1BBL demonstrates better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab associated severe toxicity. Vaccine 28:512-22, 2009.
  9. Yolcu, E.S.,  X. Gu, H. Zhao, L. Bandura-Morgan, N. Askenasy, and H. Shirwan.  Induction of tolerance to cardiac allografts using donor splenocytes engineered to display on their surface an exogenous fas ligand protein. J Immunol. 15;181:931-9, 2008.
  10. Franke, D.D.H., E.S. Yolcu, P. Alard, M.M. Kosiewicz, and H. Shirwan. A novel multimeric form of FasL modulates the ability of diabetogenic T cells to mediate type 1 diabetes in an adoptive transfer model.  Mol. Immunol. 44:2884-92, 2007.
  11. Elpek, K.G., C. Lacelle, N.P. Singh, E.S. Yolcu, and H. Shirwan. CD4+CD25+ T regulatory cells dominate multiple immune evasion mechanisms in early, but not late phases of tumor development in a B cell lymphoma model.  J. Immunol. 178:6840-8, 2007.
  12. Elpek,K.G., E.S. Yolcu, D.D.H. Franke, C. Lacelle, R.-H. Schabowsky, and H. Shirwan. Ex vivo expansion of CD4+CD25+FoxP3+ T regulatory cells based on synergy between IL-2 and 4-1BB signaling. J. Immunol. 179:295-304, 2007.
  13. Pearl-Yafe M, J. Stein, E.S.Yolcu, D.L. Farkas, H. Shirwan, I. Yaniv, and N. Askenasy. Fas transduces dual apoptotic and trophic signals in hematopoietic progenitors. Stem Cells. 25:3194-203 2007.
  14. Singh, N.P., R.W. Miller, E.S. Yolcu, M.O. Kilinc, M. Oechsli, R. Huseby, D.D. Taylor,  M.T. Perry, R.V. LaRocca, and H. Shirwan. Primary tumor cells from cancer patients decorated with a novel form of CD80 protein serve as effective antigen-presenting cells for the induction of autologous T-cell immune responses ex vivo.  Human Gene Therapy, 17:334-346, 2006.
  15. Franke, DDH and H. Shirwan. Prophylactic fenbendazole therapy does not affect the incidence and onset of type 1 diabetes in nonobese diabetic mice. Int. Immunol. 18:453-458, 2006.
  16. Kilinc, M.O., L. Mukundan, E.S. Yolcu, N. P. Singh, J. Suttles, and H. Shirwan.  Generation of a multimeric form of CD40L with potent immunostimulatory activity using streptavidin as a chaperon.  Experimental and Molecular Pathology.  Exp. Mol. Path.  80:252-6, 2006.
  17. Askenasy, N., Yolcu, E.S., Yaniv, I., and H. Shirwan.  Induction of tolerance using FasL: a double-edge immunomodulator.  Blood. 105:1396-404, 2005.
  18. Singh, N., L. Guo, X. Que, and H. Shirwan.  Blockade of the indirect recognition pathway mediated by CD4+ T cells leads to prolonged cardiac xenograft survival. Xenotransplantation 11:33-42, 2004.
  19. Askenasy, N., E. S. Yolcu, Z. Wang, and H. Shirwan. Display of Fas-ligand protein on cardiac vasculature as a novel means of regulating allograft rejection. Circulation 107:1525-31, 2003.
  20. Singh, N., E. S. Yolcu, D.T. Taylor, C. Taylor, D. Metzinger, SK Dreisbach and H. Shirwan.  A novel approach to cancer immunotherapy: tumor cells decorated with CD80 costimulatory protein serve as potent antigen-presenting cells for the generation of antitumor immunity. Cancer Research, 63:4067-4073, 2003. 
  21. Yolcu, E. S., N. Askenasy. N.P. Singh, Lamhamedi Cherradi, and H. Shirwan. Cell membrane modification for rapid display of proteins as a novel means of immunomodulation: FasL-decorated splenocytes prevent islet graft rejection.  Immunity 17:795-808, 2002.
  22. Shirwan, H. Chronic allograft rejection: do the Th2 cells preferentially induced by indirect alloantigen recognition play a dominant role?  Transplantation 68:715-26, 1999.
  23. Shirwan, H., M. Ohanjanian, G. Burcham, L. Makowka, and D.V. Cramer.  Structure and diversity of rat T-cell receptor  chain genes.  J. Immunol. 150:2295-2304, 1993
  24. Shirwan, H., K. Lewis, L. Hood, and I. Stroynowski.  Activated T cells transcribe a novelly spliced mRNA encoding a soluble form of Qa-2 molecules.  EMBO J. 9:3839-47, 1990.
Document Actions
Personal tools